Promotion: First high myopia patient free!
Repeated low-level red-light therapy has shown very strong effect in highly myopic children, with >100% efficacy and mean axial shortening and reversal of refraction diopter observed across 12 months. We are now offering clinicians a unique opportunity to trial RLRL on their high myopia patients for free, enabling them to get hands-on experience with RLRL for themselves. Your first highly myopic patient (-5D and above) can benefit from a free subscription for 2 years, only covering the device cost. For more information or to sign up your patient, please contact info@eyerisinginternational.
We see a world where myopia is controlled earlier, more easily, and more effectively.
Our eyesight is vital to learning and negotiating the world around us, and has a large impact on our potential to live full and productive lives. Myopia, also known as short-sightedness) is the most common eye disorder in the world. By 2050, it is estimated that myopia will affect one in two people.
When childhood myopia is diagnosed, it is vital to slow its progression early on. The sooner it is controlled, the better a child’s chances of maintaining long-term sight and quality of life into adulthood. However, current myopia treatments are often invasive (e.g. eye drops, contact lenses) and are not always viable for young children.
At Eyerising International, we see a world where childhood myopia is controlled earlier, more easily and more effectively. We’re working to address the global myopia epidemic by bringing our clinically proven repeated low-level red-light therapy to the next generation at home. Saving sight sooner makes for a brighter future for all of us.
Our eyesight is vital to learning and negotiating the world around us, and has a large impact on our potential to live full and productive lives. Myopia, also known as short-sightedness, is a common eye condition where distant objects appear blurred.
The Eyerising Myopia Management Device is a home-use medical device that can slow the progression of myopia in myopic children aged 3 to 16, where it works to slow the elongation of the eye. It is exclusively available through eye care professionals (e.g. optometrists, ophthalmologists).*
*Note: Outcomes may vary for each patient.
See us at upcoming events
References
- Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology, May 2016 Volume 123, Issue 5, Pages 1036?1042.
